1. |
Gaspar-Marques J, Finelli E, Martins PC, et al. Piperacillin-tazobactam anaphylaxis: a rare cause of occupational disease. Eur Ann Allergy Clin Immunol, 2018, 50(2): 89-91.
|
2. |
Bassetti M, Giacobbe DR, Robba C, et al. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors. Curr Opin Infect Dis, 2020, 33(6): 474-481.
|
3. |
Wang Q, He Z, Wu X, et al. Hematologic adverse effects induced by piperacillin-tazobactam: a systematic review of case reports. Int J Clin Pharm, 2020, 42(4): 1026-1035.
|
4. |
Kim TI, Jeong KH, Shin MK, et al. Piperacillin/tazobactam-associated hypersensitivity syndrome with overlapping features of acute generalized exanthematous pustulosis and drug-related rash with eosinophilia and systemic symptoms syndrome. Ann Dermatol, 2016, 28(1): 98-101.
|
5. |
Gallardo A, Moreno EM, Laffond E, et al. Sensitization phenotypes in immediate reactions to piperacillin-tazobactam. J Allergy Clin Immunol Pract, 2020, 8(9): 3175-3177.
|
6. |
Wong JC, Au EY, Yeung HH, et al. Piperacillin-tazobactam allergies: an exception to usual penicillin allergy. Allergy Asthma Immunol Res, 2021, 13(2): 284-294.
|
7. |
Poggiali E, Benedetti I, Vertemati V, et al. Kounis syndrome: from an unexpected case in the Emergency Room to a review of the literature. Acta Biomed, 2022, 93(1): e2022002.
|
8. |
Rico Cepeda P, Palencia Herrejón E, Rodríguez Aguirregabiria MM. Kounis syndrome. Med Intensiva, 2012, 36(5): 358-364.
|
9. |
Alblaihed L, Huis In 't Veld MA. Allergic acute coronary syndrome-Kounis syndrome. Emerg Med Clin North Am, 2022, 40(1): 69-78.
|
10. |
Sciatti E, Vizzardi E, Cani DS, et al. Kounis syndrome, a disease to know: Case report and review of the literature. Monaldi Arch Chest Dis, 2018, 88(1): 898.
|
11. |
Calogiuri GF, Nettis E, Di Leo E, et al. Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report. Int J Cardiol, 2012, 155(3): e42-44.
|
12. |
Yamashita T, Oguma Y, Kounis NG. Kounis syndrome: kill two birds with one stone. J Invasive Cardiol, 2021, 33(11): E920-E921.
|
13. |
Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis, 2005, 24(10): 649-653.
|
14. |
Rezaei NJ, Bazzazi AM, Naseri Alavi SA. Neurotoxicity of the antibiotics: A comprehensive study. Neurol India, 2018, 66(6): 1732-1740.
|
15. |
Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage. Microorganisms, 2021, 9(7): 1505.
|
16. |
Man BL, Fu YP. Piperacillin/tazobactam-induced myoclonic jerks in a man with chronic renal failure. BMJ Case Rep, 2015, 2015: bcr2015210184.
|
17. |
Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther, 2014, 36(11): 1489-1511.
|
18. |
黄雅群, 文睿婷, 于芝颖, 等. 哌拉西林及其复方制剂致过敏性休克的病例报道及文献分析. 中国药房, 2021, 32(1): 82-87.
|
19. |
周法庭, 朱晓丹, 波顺庆, 等. β-内酰胺环和侧链结构诱导青霉素类抗生素过敏的研究进展. 医学综述, 2018, 24(3): 444-448.
|
20. |
田力. 注射用哌拉西林钠他唑巴坦钠的含量测定及其配伍稳定性的考察. 大连医科大学, 2011.
|
21. |
胡丽, 黄琨, 俞仁涛. Stevens-Johnson综合征和中毒性表皮坏死松解症的疾病进展和治疗转归分析. 中国皮肤性病学杂志, 2022, 36(3): 290-294.
|
22. |
中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识. 中华皮肤科杂志, 2021, 54(5): 376-381.
|
23. |
李希国, 谢娇. 1例大疱性表皮松解坏死型药疹患者的治疗与探讨. 中国医药指南, 2011, 9(8): 139.
|
24. |
刘立立, 黄玲, 胡正波, 等. 哌拉西林钠他唑巴坦钠致大疱表皮松解型药疹1例. 中国药物警戒, 2013, 10(11): 703-704.
|
25. |
吴翠芳. 哌拉西林他唑巴坦相关性大疱性表皮坏死松解症1例. 南京: 2012年中国药学大会暨第十二届中国药师周, 2012.
|